Highlights of weekly biotech stock moves
Look for shares of Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) to move on Monday after FDA approved an NDA late Friday for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). Avanir said Nuedexta is the only drug approved by FDA for the condition, which is characterized by involuntary episodes of laughing and/or crying. The stock finished last week at $2.42, down $0.46.
Pharming Group N.V. (Euronext:PHARM) was unchanged at €0.25 last week after the EC approved an MAA for Ruconest to treat acute attacks of hereditary angioedema (HAE). Marketing and distribution partner Swedish Orphan Biovitrum AB (SSE:SOBI) was down SEK0.90 to SEK40.10 on the week.
Almirall S.A. (Madrid:ALM) fell €1.20 (15%) to €6.80 on Friday after it and partner Forest Laboratories Inc. (NYSE:FRX) reported data from the Phase III ACCORD COPD II trial of aclidinium bromide to treat chronic obstructive pulmonary disease (COPD). The